Apogee therapeutics announces positive interim phase 1 results from the apg990 healthy volunteer trial, unlocking potential maintenance dosing every three and six months for apg279 (apg777 + apg990)

Interim phase 1 results for apg990, a novel half-life extended ox40l antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life
APG Ratings Summary
APG Quant Ranking